Stock Ratings / Health Care / AMPH / dividends

AVLN (49) RAPP (43) SPTX (56) MNKD (63) ⌘ Pro Terminal →

Amphastar Pharmaceuticals Inc. (AMPH) Dividend Safety Gauge & 10-Year DRIP Compounder

$26.93 +2.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.11

Amphastar Pharmaceuticals Inc. (AMPH) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (50% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate) →

ROARABLE B- • BUY Cap $1.15B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $27.11 (+0.65%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 16.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMPH)Realized 20D OHLCV Swing Band: ±6.9%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY AMPH SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+17/20 pts (24% of score)

FRED Regime × Technicals: 80% of 52W Range • RSI-14 at 66.8 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk11/20 pts (-9 pt drag)

Balance-sheet & 10-K footnote risk deducts 9 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$26.62-2.8% Next Q

Q2 (-2Q)

Grade B-$25.87-2.8% Next Q

Q3 (-1Q)

Grade B-$25.14+7.1% Next Q

Current

Grade B-$26.93+6.8% Hist 90D α

Trajectory: C+ (63) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AMPH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, AMPH faces multiple-compression risk if 11.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 47.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($24.76) or 200D SMA ($22.25) invalidates the momentum regime and cuts Target Base ($28.51) toward Bear Floor ($22.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AMPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in AMPH & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on AMPH and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AMPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.63%▲ ASCENDING CHANNEL

2026-10-30O $27.12H $27.80L $26.76C $26.93VOL 664.5K

RES: $29.94SUP: $25.10SMA50: $24.76SMA200: $22.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AMPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AMPH Butterfly Map → + Track AMPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.0%/yr Implied 5Y Growth

vs. -1.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AMPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AMPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AMPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMPH)

Health Care Rank #85 of 1016 ⚔️ AVLN vs AMPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AMPH vs. AVLN, RAPP, SPTX, MNKD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Amphastar Pharmaceuticals Inc. (AMPH) ranks #85 by composite RQD confidence (71/100, grade B-) and #343 by equity capitalization ($1.15B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AMPH ACTIVE Amphastar Pharmaceuticals Inc.	B-	71/100	11.7x	49.5%	9.0%	+2.28%	$1.15B	Benchmark Subject
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-amph →
RAPP Rapport Therapeutics Inc.	D-	43/100	—	—	-22.9%	+7.60%	$1.16B	/rapp-vs-amph →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-amph →
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-amph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001297184

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amphastar Pharmaceuticals Inc. (AMPH) reported GAAP revenue of $719.9M (-1.7% vs. FY2024 revenue of $732.0M , and +11.7% cumulative change since FY2023) , GAAP net income of $98.1M, operating cash flow of $156.1M, and free cash flow of $121.2M (-29.7% YoY). On the balance sheet, AMPH closed FY2025 with $1.63B in total assets against $619.7M in total debt (Altman Z-Score: 2.47, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$719.9M	$98.1M	$156.1M	$121.2M	$1.63B	$619.7M
FY2024 (FY)	2024-12-31	$732.0M	$159.5M	$213.4M	$172.3M	$1.58B	$613.5M
FY2023 (FY)	2023-12-31	$644.4M	$137.5M	$183.5M	$183.5M	—	—

3. AMPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AMPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $26.93 (+2.28% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, AMPH ranks #85 in composite RQD confidence.

How does AMPH compare to AVLN and RAPP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMPH carries a Roarable B- (71/100 RQD), trailing P/E of 11.7x, gross margin of 49.5%, and ROIC of 9.0%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.14B) and RAPP (Rapport Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AMPH?

Per AMPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001297184), Amphastar Pharmaceuticals Inc. generated $719.9M in revenue (-1.7% YoY), $98.1M in net income, and $121.2M in free cash flow against $1.63B in total assets and $619.7M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AMPH trading relative to its 50-day, 200-day, and 52-week technical levels?

AMPH last traded at $26.93 (+2.28% on volume of 371,432 shares), positioning the stock +8.76% above its 50-day simple moving average ($24.76) and +21.03% above its 200-day simple moving average ($22.25). Across its 52-week range of $16.65 to $29.52, AMPH sits at the 79.9% percentile with a 14-day RSI of 66.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.9% ($25.07 to $28.79).

AMPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does AMPH pay a dividend and is it safe?

Amphastar Pharmaceuticals Inc. (AMPH) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: AMPH RQD Cockpit AMPH 12M Forecast AMPH Earnings & Move AMPH Dividends & DRIP AMPH Insiders & 13F AMPH Whale Options AMPH Profit Sankey AMPH News & Why